V8 Peptides — Engineered Performance
Research Library
PT-141 vs MT-2: Formula, Mass and Analytical Differences
PT-141Comparison

PT-141 vs MT-2: Formula, Mass and Analytical Differences

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How do PT-141 and MT-2 differ chemically? By one terminal group: a free carboxylic acid (PT-141, C50H68N14O10) versus a primary amide (MT-2, C50H69N15O9). Calculated average molar masses are about 1,025.18 and 1,024.20 g/mol, a gap of roughly 0.98. HPLC purity cannot confirm which is in a vial; identity needs a method that resolves one dalton. Both are supplied for laboratory research use only.

PT-141 and MT-2 (melanotan II) are often mentioned in the same breath because their structures are almost the same. That similarity is exactly what makes them awkward to tell apart on paper and in an instrument. This article is a chemistry-and-analytics comparison: formulas, masses, charge, what each difference means for a chromatography or mass-spectrometry experiment, and what a laboratory can and cannot conclude from the documentation that accompanies a vial. It does not compare outcomes, and it makes no claim about what either molecule does beyond what the V8 product pages and the cited literature state. For the experimental-design side of the pairing, see the library's broader PT-141 vs melanotan II comparison.

The two product pages give the facts used here. The PT-141 page lists formula C50H68N14O10, sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, a 10 mg vial and purity of at least 98% by HPLC. The MT-2 page lists C50H69N15O9, the same sequence ending in -NH2, a 10 mg vial and the same purity statement. Both are lyophilized powders stored refrigerated at 2–8 °C, or at −20 °C long term, protected from heat, moisture and light, and both are for laboratory research use only.

The one-group difference, in numbers

Swap a carboxylic acid (–COOH) for a primary amide (–CONH2) and the formula gains a nitrogen and a hydrogen while losing an oxygen. That is exactly the difference between the two formulas above. Calculating from standard atomic weights, the average molar mass of PT-141 comes to about 1,025.18 g/mol and that of MT-2 to about 1,024.20 g/mol, a gap of 0.98. On a monoisotopic basis, which is what a high-resolution mass spectrometer reports, the neutral masses are about 1,024.524 and 1,023.540 Da, and the singly protonated ions, [M+H]+, sit near m/z 1,025.53 and 1,024.55. The table sets the values side by side; they are calculated from the formulas on the product pages, not measured values from any lot.

PropertyPT-141MT-2 (melanotan II)
Formula (product page)C50H68N14O10C50H69N15O9
C-terminal groupFree carboxylic acid (–OH)Primary amide (–NH2)
Average molar mass (calculated)about 1,025.18 g/molabout 1,024.20 g/mol
Monoisotopic mass (calculated)about 1,024.524 Daabout 1,023.540 Da
[M+H]+ (calculated)about m/z 1,025.53about m/z 1,024.55
Vial size listed10 mg10 mg
Purity statement≥98% by HPLC≥98% by HPLC

The most important number is the one-dalton gap. A low-resolution instrument that reports nominal mass might confuse the two, and a natural isotopic envelope complicates the picture: the carbon-13 satellite of the lighter amide species lands close to the monoisotopic peak of the acid. Resolving the pair therefore benefits from an instrument and a method that report the isotopic pattern clearly, or from comparing retention time against an authentic reference of each.

Charge, polarity and chromatographic behaviour

In the ring, the aspartic acid carboxyl and the lysine amine are consumed by the lactam bridge, so neither contributes a charge. What remains charged are the arginine side chain, the histidine imidazole in its pH-dependent state, and the terminal group. An amide terminus is neutral at all practical pH values. A carboxylic acid is largely deprotonated at neutral pH and carries a negative charge, which offsets part of the arginine's positive charge. At the low pH typical of reversed-phase HPLC mobile phases with an ion-pairing acid, the carboxylic acid is protonated and neutral, so the retention difference between the two compounds on a standard C18 method is expected to be small and cannot be assumed. That is a prediction from general chemistry and not a measured value for either lot.

For that reason, a one-point "retention time matches" check says little. A more reliable approach is to run both compounds, where available, under the same method and look at the separation between them, then run the unknown with and without spiking in one of the references. Optimizing the gradient and column temperature can open a small difference into a visible separation; the underlying principles are described in understanding HPLC purity and HPLC vs mass spectrometry.

What the sequences leave identical

Everything except the terminus is the same: the N-terminal acetylated norleucine, the aspartic acid and lysine closing the ring, the His-D-Phe-Arg-Trp core, and the molecular scaffold. A review of melanocortin analogs places PT-141 as a new analog of melanotan II (Hadley and Dorr, 2006), which accords with the sequences. The shared features include the weak points: tryptophan and histidine as oxidation-prone residues, an amide-linked ring that survives reducing buffers, and a preference for protection from heat, moisture and light. Because the stability profile is largely common to both, one storage routine serves either vial, and a lab handling both does not need two sets of rules. The general logic is covered in storing research peptides.

The shared core also explains why both appear in the same assays. Norleucine and D-phenylalanine at the positions shown were introduced in early α-MSH analog work, where the 4-norleucine, 7-D-phenylalanine analog was resistant to serum enzymes and far more potent than the native hormone in an adenylate cyclase assay (Sawyer et al., 1980). The analogs built on the same recognition motif inherit the logic, and the product pages for both compounds describe them as melanocortin receptor agonists, MT-2 in terms of MC1R and MC4R work and melanogenesis models and PT-141 in terms of MC3R and MC4R work.

Impurity profiles: what could differ and what could be shared

Synthesis and purification leave characteristic by-products. A review of related impurities in peptide medicines catalogues deletion and truncation products, racemized forms, incompletely deprotected chains and side-chain modifications that arise on solid-phase assembly (D'Hondt et al., 2014), and Fmoc chemistry, the dominant route, has its own well-documented behaviours (Behrendt et al., 2016). Both compounds share the same assembly challenges, so a related-substances profile should look similar in kind. The terminal group, however, creates a pair of special cases. The amide is typically produced by cleaving the finished peptide from an amide-forming resin, while the acid comes from an acid-forming resin; a mix-up of resin or a cross-contamination in a shared workflow would show up as a minor peak at the other compound's mass. A laboratory that cares about cross-contamination at the percent level should ask whether the analytical method can see a one-dalton neighbour.

  • Check identity at high resolution when an acid-versus-amide question matters to the experiment.
  • Look for the neighbour: inspect the mass spectrum at +0.98 Da and −0.98 Da from the main species for a minor contribution.
  • Compare like with like: run both compounds under identical chromatographic conditions in the same session.
  • Record the method: column, gradient, temperature and wavelength belong in the notebook beside the lot number.

Counterion and water: the part of the label mass that is not peptide

Both vials contain a nominal 10 mg of powder, and for neither does the label say how much of that is peptide. Reversed-phase purification often leaves a trifluoroacetate salt, and in cell culture trifluoroacetate at 10–100 nM has been reported to reduce proliferation of osteoblast cultures, with similar findings in chondrocytes (Cornish et al., 1999). Counterion content depends on the number of basic sites, and the two compounds do not differ meaningfully there, since they have the same ionizable side chains. Concentration arithmetic should use the molar masses above, C = m ÷ (M × V), with the nominal mass regarded as an upper bound for peptide; the calculator performs it and peptide reconstitution volume calculations explains the variables. Because the molar masses differ by only 0.1%, equal-mass and equimolar comparisons of the two compounds are practically the same; the more significant uncertainty is peptide content, which is not stated.

Reading the documentation for each vial

The product pages for both compounds list the same documentation items: identity and sequence, measured purity as an HPLC percentage, sequence or identity confirmation, batch or lot number, analytical test date, and supplied form and storage. Both pages currently mark the certificate of analysis as in progress, so the right interpretation is that the analytical record for that lot is not yet published. Where a certificate is available, it can be found through the COA page, and how to read a COA explains what each field means.

Documentation item listedPT-141 pageMT-2 page
Compound identity and sequenceListedListed
Measured purity (HPLC %)ListedListed
Sequence or identity confirmationListedListed
Batch or lot number; test dateListedListed
Supplied form and storageListedListed
Certificate statusIn progress (at time of writing)In progress (at time of writing)

The two points to look for in a pair like this one are the identity method (can it separate acid from amide?) and the date.

Sourcing questions for each are in where to buy PT-141 and where to buy melanotan II, and quality-focused reading is in PT-141 purity testing and melanotan II purity testing.

Summary

PT-141 and MT-2 differ by one terminal group, a calculated 0.98 Da, and a negligible 0.1% in molar mass. Everything else in the structure, and most of the handling guidance, is shared. The difference is large enough to matter for identity and mislabelling questions, and small enough that a purity number cannot settle them. A laboratory working with either compound, or both, should confirm identity with a method that resolves one dalton, record the method and lot, and keep any claim about biological differences to what its own assays show. Both are supplied for laboratory research use only; the catalogue is on the shop page, and the parent compound is described in the melanotan II research overview.

Frequently asked questions

What is the chemical difference between PT-141 and MT-2?

Only the C-terminus: PT-141 ends in a free carboxylic acid and MT-2 (melanotan II) ends in a primary amide. Their formulas on the product pages are C50H68N14O10 and C50H69N15O9.

How much do their masses differ?

Calculated from the formulas, the average molar mass is about 1,025.18 g/mol for PT-141 and 1,024.20 g/mol for MT-2, a difference of about 0.98.

Can HPLC alone tell PT-141 from MT-2?

Not reliably. A single-peak chromatogram shows homogeneity, and the two compounds are expected to elute close together. Identity needs a mass-resolving method or a spiking experiment against an authentic reference.

What does a mass spectrometer see?

Calculated [M+H]+ values are near m/z 1,025.53 for PT-141 and 1,024.55 for MT-2, separated by about 0.98. The method has to resolve isotopic envelopes to tell them apart.

Do the two compounds need different storage?

Both product pages give the same storage guidance: 2–8 °C, −20 °C for long-term storage, and protection from heat, moisture and light.

Are the compounds sold in the same vial size?

Yes. Each page lists a 10 mg vial of lyophilized powder with a purity statement of at least 98% by HPLC.

Does equal mass mean equal molarity?

Almost. The molar masses differ by about 0.1%, so equal masses of powder are practically equimolar if peptide content is the same, which the label does not state.

Why mention counterions?

Peptides are often supplied as trifluoroacetate salts, and trifluoroacetate has been reported to reduce proliferation in osteoblast and chondrocyte cultures (Cornish et al., 1999). It is part of the reagent in sensitive cell assays.

Where do I find documentation for each lot?

The product pages list the documentation items, and the COA page lists published certificates. Both pages currently mark the certificate as in progress, so lot identity and purity are unverified until published.

Are either of these sold for use outside the laboratory?

No. Both are supplied strictly for laboratory research use only and are not intended for human or animal consumption.

Related reading: PT-141 vs MT-2: Choosing a Melanocortin Reference Ligand, PT-141 Reconstitution for In Vitro Assays, PT-141 in Receptor Binding and cAMP Assays.

References

  1. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029
  2. Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone: a highly potent α-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77(10):5754-5758. doi:10.1073/pnas.77.10.5754
  3. D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. doi:10.1016/j.jpba.2014.06.012
  4. Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4-27. doi:10.1002/psc.2836
  5. Cornish J, Callon KE, Lin CQ, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999;277(5):E779-E783. doi:10.1152/ajpendo.1999.277.5.e779

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.